A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Lamivudine/abacavir
- Indications HIV infections
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 07 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Mar 2018.
- 07 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2017.
- 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.